Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.

Geert R A M D'HaensPeter D R HigginsLaurent Peyrin-BirouletBruce E SandsScott LeeRichard E MosesIsabel RedondoRodrigo EscobarTheresa Hunter GibbleAnthony KeohaneNathan MorrisXin ZhangVipin AroraTaku Kobayashi

Published in: Inflammatory bowel diseases (2024)

With "extended induction," total of 80.3% mirikizumab-treated patients achieved clinical response by W24. Potential prognostic factors determining response include disease severity, disease phenotype, C-reactive protein, and previous biologic therapy.

Keyphrases

prognostic factors
newly diagnosed
ulcerative colitis
end stage renal disease
rheumatoid arthritis
stem cells
human health